Age Related Macular Degeneration Stocks List

Recent Signals

Date Stock Signal Type
2021-05-06 GHSI Bollinger Band Squeeze Range Contraction
2021-05-06 IRIX 1,2,3 Pullback Bullish Bullish Swing Setup
2021-05-06 IRIX Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-05-06 IRIX 20 DMA Resistance Bearish
2021-05-06 ISEE Upper Bollinger Band Walk Strength
2021-05-06 NGM Doji - Bullish? Reversal
2021-05-06 NGM 20 DMA Support Bullish
2021-05-06 OTLK Fell Below 50 DMA Bearish
2021-05-06 OTLK 20 DMA Support Bullish
2021-05-06 TCON Lower Bollinger Band Walk Weakness
2021-05-06 TCON Expansion Breakdown Bearish Swing Setup

Recent News for Age Related Macular Degeneration Stocks

Date Stock Title
May 6 NGM NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Tops Revenue Estimates
May 6 NGM NGM Biopharmaceuticals EPS beats by $0.05, misses on revenue
May 6 NGM NGM Bio Provides Business Highlights and Reports First Quarter 2021 Financial Results
May 6 TCON TRACON Pharmaceuticals (TCON) CEO Charles Theuer on Q1 2021 Results - Earnings Call Transcript
May 6 AGTC Applied Genetic's XLRP Gene Therapy Shows Improved, Durable Response In Retinal Sensitivity
May 6 AGTC AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinical Trial
May 6 ISEE IVERIC bio, Inc. (ISEE) Q1 2021 Earnings Call Transcript
May 5 TCON Tracon EPS misses by $0.03
May 5 AGTC AGTC to Host Conference Call on May 6 at 8:00 AM ET to Discuss XLRP Full 12-Month Data from Highest Dose Groups and 24-Month Data from a Subset of Group 4 Patients of its Ongoing Phase 1/2 Clinical Trial
May 5 TCON TRACON Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 5 ISEE IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q1 2021 Results - Earnings Call Transcript
May 5 NGM Earnings Preview: NGM Biopharmaceuticals (NGM) Q1 Earnings Expected to Decline
May 5 AGTC Editas strengthens Q1 liquidity despite rising net loss; names new chief scientific officer
May 5 ISEE IVERIC bio EPS misses by $0.04
May 5 ISEE Iveric Bio Reports First Quarter 2021 Operational Highlights and Financial Results
May 4 IRIX Earnings Preview: Iridex (IRIX) Q1 Earnings Expected to Decline
May 4 AGTC AGTC Advances in AAV Gene Therapy Manufacturing to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting
May 3 AGTC AGTC Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials
May 3 GHSI Guardion Health initiates GlaucoCetin glaucoma trial
May 3 GHSI Guardion Health Sciences Initiates Placebo-Controlled Clinical Trial Involving Proprietary GlaucoCetin® Product

Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Early on there are often no symptoms. Over time, however, some people experience a gradual worsening of vision that may affect one or both eyes. While it does not result in complete blindness, loss of central vision can make it hard to recognize faces, drive, read, or perform other activities of daily life. Visual hallucinations may also occur but these do not represent a mental illness.Macular degeneration typically occurs in older people. Genetic factors and smoking also play a role. It is due to damage to the macula of the retina. Diagnosis is by a complete eye exam. The severity is divided into early, intermediate, and late types. The late type is additionally divided into "dry" and "wet" forms with the dry form making up 90% of cases.Preventive efforts include exercising, eating well, and not smoking. Antioxidant vitamins and minerals do not appear to be useful for prevention. There is no cure or treatment that returns vision already lost. In the wet form, anti-VEGF medication injected into the eye or less commonly laser coagulation or photodynamic therapy may slow worsening. Supplements in those who already have the disease may slow progression.In 2015 it affected 6.2 million people globally. In 2013 it was the fourth most common cause of blindness after cataracts, preterm birth, and glaucoma. It most commonly occurs in people over the age of fifty and in the United States is the most common cause of vision loss in this age group. About 0.4% of people between 50 and 60 have the disease, while it occurs in 0.7% of people 60 to 70, 2.3% of those 70 to 80, and nearly 12% of people over 80 years old.

More about Age Related Macular Degeneration
Browse All Tags